JPWO2022231978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022231978A5 JPWO2022231978A5 JP2023565628A JP2023565628A JPWO2022231978A5 JP WO2022231978 A5 JPWO2022231978 A5 JP WO2022231978A5 JP 2023565628 A JP2023565628 A JP 2023565628A JP 2023565628 A JP2023565628 A JP 2023565628A JP WO2022231978 A5 JPWO2022231978 A5 JP WO2022231978A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- pharmaceutical formulation
- seq
- antibody pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 13
- 229960002885 histidine Drugs 0.000 claims 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 7
- 229930182817 methionine Natural products 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 6
- 229920000053 polysorbate 80 Polymers 0.000 claims 6
- 229940068968 polysorbate 80 Drugs 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- 239000012141 concentrate Substances 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 229920000136 polysorbate Polymers 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 229950008882 polysorbate Drugs 0.000 claims 3
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 229940068965 polysorbates Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001219 Polysorbate 40 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940101027 polysorbate 40 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179879P | 2021-04-26 | 2021-04-26 | |
| US63/179,879 | 2021-04-26 | ||
| PCT/US2022/026005 WO2022231978A1 (en) | 2021-04-26 | 2022-04-22 | Anti-gal3 antibody formulations and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515968A JP2024515968A (ja) | 2024-04-11 |
| JPWO2022231978A5 true JPWO2022231978A5 (enExample) | 2025-04-28 |
Family
ID=83848624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565628A Pending JP2024515968A (ja) | 2021-04-26 | 2022-04-22 | 抗ｇａｌ３抗体製剤およびその使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240158512A1 (enExample) |
| EP (1) | EP4329804A4 (enExample) |
| JP (1) | JP2024515968A (enExample) |
| CN (1) | CN117561080A (enExample) |
| WO (1) | WO2022231978A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2025064944A1 (en) * | 2023-09-20 | 2025-03-27 | Vor Biopharma Inc. | Anti-cd45 antibody-drug conjugate pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| WO2018204374A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| CN116063520A (zh) * | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) * | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
-
2022
- 2022-04-22 CN CN202280045350.2A patent/CN117561080A/zh active Pending
- 2022-04-22 WO PCT/US2022/026005 patent/WO2022231978A1/en not_active Ceased
- 2022-04-22 JP JP2023565628A patent/JP2024515968A/ja active Pending
- 2022-04-22 EP EP22796456.6A patent/EP4329804A4/en active Pending
-
2023
- 2023-10-23 US US18/492,607 patent/US20240158512A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020244614B2 (en) | Stable protein solution formulation containing high concentration of an anti-VEGF antibody | |
| CN111315411B (zh) | 高浓度抗c5抗体制剂 | |
| AU2005330672B2 (en) | Stabilized anti-hepatitis B (HBV) antibody formulations | |
| JP2022036932A5 (enExample) | ||
| JP2008528638A5 (enExample) | ||
| WO2013164789A2 (en) | Antibody formulatoin | |
| IL268202B2 (en) | Anti-rsv monoclonal antibody formulation | |
| CN110732023A (zh) | 一种her2抗体药物组合物及其用途 | |
| JP2019532970A5 (enExample) | ||
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| WO2005072772A1 (en) | Pharmaceutical compositions | |
| WO2022017468A1 (zh) | Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JPWO2022231978A5 (enExample) | ||
| JPWO2020243031A5 (enExample) | ||
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JPWO2023086817A5 (enExample) | ||
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| JPWO2023019171A5 (enExample) | ||
| JPWO2022043900A5 (enExample) | ||
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| TW202124454A (zh) | 抗ｐｃｓｋ９抗體用於預防或治療膽固醇相關疾病的方法 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| JP2024522165A (ja) | ２０１９新型コロナウイルス抗体含有医薬製剤 | |
| JPWO2021101975A5 (enExample) |